ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 109 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2016. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $294 | -29.5% | 300 | 0.0% | 0.00% | – |
| Q2 2023 | $417 | -12.6% | 300 | 0.0% | 0.00% | – |
| Q1 2023 | $477 | -74.5% | 300 | 0.0% | 0.00% | – |
| Q4 2022 | $1,869 | -6.6% | 300 | 0.0% | 0.00% | – |
| Q3 2022 | $2,000 | 0.0% | 300 | 0.0% | 0.00% | – |
| Q2 2022 | $2,000 | 0.0% | 300 | 0.0% | 0.00% | – |
| Q4 2021 | $2,000 | -66.7% | 300 | 0.0% | 0.00% | – |
| Q2 2021 | $6,000 | -25.0% | 300 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $8,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $8,000 | -27.3% | 300 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $11,000 | -26.7% | 300 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $15,000 | +66.7% | 300 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $9,000 | -50.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $18,000 | +63.6% | 300 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $11,000 | -21.4% | 300 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $14,000 | +16.7% | 300 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $12,000 | -14.3% | 300 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $14,000 | +7.7% | 300 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $13,000 | +8.3% | 300 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $12,000 | -45.5% | 300 | 0.0% | 0.00% | -50.0% |
| Q1 2018 | $22,000 | +10.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $20,000 | +33.3% | 300 | 0.0% | 0.00% | +100.0% |
| Q3 2017 | $15,000 | +7.1% | 300 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $14,000 | +27.3% | 300 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $11,000 | +175.0% | 300 | 0.0% | 0.00% | – |
| Q4 2016 | $4,000 | 0.0% | 300 | 0.0% | 0.00% | -100.0% |
| Q3 2016 | $4,000 | +33.3% | 300 | 0.0% | 0.00% | – |
| Q2 2016 | $3,000 | -40.0% | 300 | 0.0% | 0.00% | -100.0% |
| Q1 2016 | $5,000 | -28.6% | 300 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $7,000 | +75.0% | 300 | +100.0% | 0.00% | 0.0% |
| Q3 2015 | $4,000 | -50.0% | 150 | +50.0% | 0.00% | 0.0% |
| Q2 2015 | $8,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |